Article Sidebar
Published:
Nov 13, 2020DOI:
10.4314/tjpr.v19i6.9Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Amygdalin protects apoptosis of retinal ganglionic cells in glaucoma rats by regulating the expressions of anti- and pro-apoptotic proteins
Abstract
Purpose: To evaluate the protective effect of amygdalin against glaucoma.
Methods: Glaucoma was induced in rats via ischemia/reperfusion. The rats were treated with amygdalin (1 mg/kg) intraperitoneally (ip) for 5 weeks. Intra-ocular pressure (IOP), viability of retinal ganglion cell (RGCs) and histopathological changes in the retinal tissue of the glaucoma rats were determined. The expression levels of inflammatory cytokines and expressions of apoptotic factors were assessed in retinal tissues of all groups.
Results: Intra-ocular pressure was reduced in amygdalin-treated group, when compared with the glaucoma group (p < 0.05). Moreover, the viability and thickness of RGCs in the amygdalin-treated group were enhanced, relative to untreated glaucoma rats. There was decrease in retinal cytokine
levels in amygdalin-treated group, when compared with untreated glaucoma rats. Amygdalin treatment ameliorated altered expressions of apoptosis proteins in the retinal tissue of ischemia/reperfusioninduced glaucoma rats.
Conclusion: Amygdalin has a protective effect against ischemia/reperfusion-induced glaucoma in rats. Thus, it has a potential for use in the clinical management of glaucoma.
Keywords: Glaucoma, Amygdalin, Cytokines, Ischemia/reperfusion, Apoptosis
